Stock AnalizZimmer Biomet Holdings, Inc. ZBH
Industrial Specialties · data as of November 13, 2026
Zimmer Biomet Holdings, Inc. (ZBH) is a healthcare company listed in the US with a market value of about $19.5B. In the twelve months to September 30, 2026 it had revenue of $8.6B and net income of $767M, a net margin of 9.0%.
Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is shareholder returns (5/5); the weakest is value (1/5).
Key numbers: a P/E of 26.1, a price to free cash flow of 11.9, 5-year revenue growth of 6% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 12% below the current price.
Score: 2.2 / 5
Checks passed
- P/FCF below 20
- Strong R&D investment or growth above 20%
- Profitable 5 years in a row
- Positive free cash flow
- Interest covered more than 5 times
- Liabilities below 60% of assets
- Pays a dividend
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.6B | $8.2B | $7.7B | $7.4B | $6.9B | $6.8B | $6.1B | $8.0B | $7.9B | $7.8B | $7.7B |
| Net income | $767M | $705M | $904M | $1.0B | $231M | $402M | -$139M | $1.1B | -$379M | $1.8B | $306M |
| Free cash flow | $1.6B | $1.5B | $1.3B | $1.3B | $1.2B | $1.4B | $1.1B | $1.4B | $1.6B | $1.4B | $1.4B |
| EPS (diluted) | $3.96 | $3.55 | $4.43 | $4.88 | $1.10 | $1.91 | $-0.67 | $5.47 | $-1.86 | $8.90 | $1.51 |
| Net margin | 9.0% | 8.6% | 11.8% | 13.9% | 3.3% | 5.9% | -2.3% | 14.2% | -4.8% | 23.2% | 4.0% |
| ROIC | — | 4.6% | 5.9% | 6.6% | 2.8% | 3.8% | 0.3% | 4.3% | 0.1% | 2.9% | 3.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $116.19, 13% above the current price; targets range from $98.00 to $130.00; the consensus rating is “Buy”; expected EPS is $8.55 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Zimmer Biomet’s P/E ratio?
About 26.1, based on the last twelve months of diluted earnings per share (forward P/E about 11.4).
Is Zimmer Biomet stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 12% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Zimmer Biomet pay a dividend?
Yes. The dividend yield is about 0.93%, and it has paid dividends for 10 years in our data.
Is Zimmer Biomet a good stock to buy?
We do not give buy or sell advice. Zimmer Biomet scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.